Scope, Claims, and Patent Landscape for US Drug Patent 9,949,997 (Empagliflozin)
US 9,949,997 is a method-of-treatment patent directed to empagliflozin in type 2 diabetes mellitus patients who have cardiovascular disease, with specified oral daily dosing of 10 mg or 25 mg. The claim set is structured around three cardiovascular outcomes (cardiovascular death, hospitalization for heart failure, and all-cause mortality) and a parallel set of product-formulation/dose-size sub-claims (10 mg or 25 mg compositions), plus explicit dosage-dependent dependent claims.
What is US 9,949,997 claiming in plain scope terms?
Core independent claim scope (Claim 1)
Claim 1 defines a method that requires all of the following elements:
- Patient population: type 2 diabetes mellitus
- Condition/comorbidity: cardiovascular disease
- Therapy: administering empagliflozin
- Route: oral
- Total daily dose: 10 mg or 25 mg
- Therapeutic outcome: reduction in risk of cardiovascular death
This is not a broad “empagliflozin use for CV risk reduction” claim; it is confined to:
- the specific patient phenotype (T2DM with cardiovascular disease),
- a specific outcome (CV death),
- and specific dosing band (10 mg or 25 mg daily, orally).
Outcome variants (Independent claim set logic)
From the text provided, Claims 3 and 5 provide the second and third outcome pillars:
- Claim 3: reduces risk of hospitalization for heart failure in T2DM patients with cardiovascular disease; empagliflozin oral daily 10 mg or 25 mg
- Claim 5: reduces risk of all-cause mortality in T2DM patients with cardiovascular disease; empagliflozin oral daily 10 mg or 25 mg
So the practical claim “map” is:
| Outcome targeted |
Claims covering it |
Dose/route requirement |
| Cardiovascular death |
1 |
Oral; 10 mg or 25 mg total daily |
| Hospitalization for heart failure |
3 |
Oral; 10 mg or 25 mg total daily |
| All-cause mortality |
5 |
Oral; 10 mg or 25 mg total daily |
Formulation/dose sub-claims (Claims 2, 4, 6 and 9–18)
Claims 2, 4, and 6 attach a pharmaceutical composition limitation to the respective method claims:
- Claim 2 depends on Claim 1: composition comprises 10 mg or 25 mg empagliflozin
- Claim 4 depends on Claim 3: composition comprises 10 mg or 25 mg empagliflozin
- Claim 6 depends on Claim 5: composition comprises 10 mg or 25 mg empagliflozin
Then Claims 9–10, 13–14, 17–18 specify whether the composition contains 10 mg or 25 mg. Claims 7–8, 11–12, 15–16 similarly specify whether the administration is 10 mg or 25 mg as a total daily oral dose.
Result: the claim family is tightly aligned to the two standard empagliflozin dose strengths (10 mg and 25 mg daily) used in cardiovascular outcome programs.
How is the claim structure likely to behave in enforcement and design-around?
What a typical infringement theory would look like
Infringement of these method claims usually tracks real-world prescribing and labeling-compatible use:
- A clinician prescribes empagliflozin to a T2DM + cardiovascular disease patient
- The regimen is oral and at 10 mg/day or 25 mg/day total daily
- The claimed endpoints are the clinical risks being reduced (as defined by the patent’s treatment effect)
Because Claims 1, 3, and 5 are methods, enforcement typically focuses on the acts of administration and patient selection rather than on manufacturing per se.
What is most useful for a design-around
Given the explicit limitations, meaningful design-around vectors are constrained:
- Dose-specific limitation: the claims cover only 10 mg or 25 mg daily. A regimen that uses a different dose (if clinically and commercially viable) could reduce exposure for those particular method claims.
- Outcome specificity: even if empagliflozin reduces some cardiovascular metric, the claim is outcome-defined: CV death, HF hospitalization, or all-cause mortality.
- Population selection: cardiovascular disease is an express condition. Empagliflozin use outside that population (even in T2DM) can fall outside claim coverage.
The presence of composition sub-claims also creates a second enforcement lane for product makers supplying fixed-dose tablets, where “10 mg” and “25 mg” composition strengths map directly to the claim language.
What is the practical “claim chart” for the independent method claims?
Claim 1 (Cardiovascular death reduction)
| Element |
Required limitation |
| Method type |
method to reduce risk of cardiovascular death |
| Patient |
patient with type 2 diabetes mellitus |
| Additional status |
patient has cardiovascular disease |
| Drug |
administering empagliflozin |
| Route |
oral |
| Dose |
total daily amount 10 mg or 25 mg |
| Result |
risk of cardiovascular death reduced |
Claim 3 (HF hospitalization reduction)
| Element |
Required limitation |
| Method type |
method to reduce risk of hospitalization for heart failure |
| Patient |
T2DM |
| Additional status |
cardiovascular disease |
| Drug |
administering empagliflozin |
| Route |
oral |
| Dose |
total daily amount 10 mg or 25 mg |
| Result |
risk of hospitalization for heart failure reduced |
Claim 5 (All-cause mortality reduction)
| Element |
Required limitation |
| Method type |
method to reduce risk of all-cause mortality |
| Patient |
T2DM |
| Additional status |
cardiovascular disease |
| Drug |
administering empagliflozin |
| Route |
oral |
| Dose |
total daily amount 10 mg or 25 mg |
| Result |
risk of all-cause mortality reduced |
How broad are the dependent claims (7–18)?
The dependent claims mainly create clean, enforceable slices:
- Claims 7–8, 11–12, 15–16: administration is restricted to either 10 mg or 25 mg daily.
- Claims 9–10, 13–14, 17–18: composition contains 10 mg or 25 mg empagliflozin.
This matters because it reduces ambiguity. A litigant can frame infringement around the exact marketed tablet strength and exactly what dosing regimen is prescribed.
Where does US 9,949,997 sit in the empagliflozin patent landscape?
Relationship to known empagliflozin IP layers (functional map)
Empagliflozin’s IP landscape in the US generally spans at least three layers:
- Compound / composition-of-matter
- Formulation / dosage form
- Method-of-use (clinical outcome claims) tied to specific patient populations, dosing, and endpoints
US 9,949,997 is squarely in layer 3: method-of-treatment focused on cardiovascular outcomes in a T2DM patient subgroup with cardiovascular disease and dosing at 10 mg or 25 mg orally.
What this implies for competition and time-to-entry
- If a competitor files for generic empagliflozin, product manufacturing may not be blocked by method claims, but labeling and “carve-out” strategies often matter to avoid indirect exposure.
- For branded incumbents, method claims can extend practical exclusivity by limiting how competitors can market or induce use.
- For other SGLT2 inhibitors, the key IP question is not “do they inhibit SGLT2,” but whether they meet the same combination of patient selection + dosing + outcome logic.
How does this claim set interact with real-world clinical endpoints?
Even without re-stating trial names, the claim endpoints match the standard cardiovascular outcome categories used in regulatory and clinical programs for SGLT2 inhibitors:
- cardiovascular death
- hospitalization for heart failure
- all-cause mortality
The claim structure reflects that outcome-anchored evidence is converted into:
- independent outcome claims (1, 3, 5)
- dose-strength dependent claims (7–8, 11–12, 15–16)
- composition dose-strength dependent claims (9–10, 13–14, 17–18)
That combination improves enforceability because a fact pattern with T2DM + cardiovascular disease and a 10 mg or 25 mg daily regimen naturally maps to the dependent slices.
What is the likely litigation leverage of these claims?
Strengths
- Tight limitations: patient type (T2DM), additional subgroup (cardiovascular disease), route (oral), and dose (10 mg/25 mg).
- Outcome specificity: each independent claim is tied to a clinically measurable endpoint.
- Dose-splitting dependent claims: provides fallback theories for either the 10 mg or 25 mg regimen even if one dose is disputed.
Vulnerabilities
- Key interpretive pressure points: “cardiovascular disease” needs construction in the evidentiary record of what constitutes inclusion, and the risk-reduction language needs to map to the patent’s defined clinical interpretation.
- Design-around by dose: because the claims are limited to 10 mg and 25 mg, any non-covered dosing regimen can be a strategic lever.
- Off-label or alternative dosing: if a competitor or prescriber uses a dosing strength outside 10/25 daily, it may reduce the direct fit.
Patent landscape: where the bottleneck typically is for competitors
For companies assessing entry risk or label strategy, the relevant landscape question becomes:
- Are there multiple method-of-use patents covering empagliflozin’s cardiovascular outcomes in T2DM with cardiovascular disease, each with different claim formats (dose, patient subgroup, endpoint)?
- Is US 9,949,997 one of those anchor patents, covering multiple endpoints with dose-linked claims?
Based on the claim text alone, the patent is structured as an “anchor” because it covers three outcome categories under one umbrella and repeats the dose strengths in dependent claims.
Claim-by-claim scope table (from the user-provided claims)
| Claim |
What it covers |
Key limitations |
| 1 |
Reduce risk of cardiovascular death |
T2DM + cardiovascular disease; empagliflozin; oral; 10 mg or 25 mg/day |
| 2 |
Composition variant for Claim 1 |
composition comprises 10 mg or 25 mg empagliflozin |
| 3 |
Reduce risk of hospitalization for heart failure |
T2DM + cardiovascular disease; empagliflozin; oral; 10 mg or 25 mg/day |
| 4 |
Composition variant for Claim 3 |
composition comprises 10 mg or 25 mg empagliflozin |
| 5 |
Reduce risk of all-cause mortality |
T2DM + cardiovascular disease; empagliflozin; oral; 10 mg or 25 mg/day |
| 6 |
Composition variant for Claim 5 |
composition comprises 10 mg or 25 mg empagliflozin |
| 7 |
Claim 1 dose slice |
10 mg/day |
| 8 |
Claim 1 dose slice |
25 mg/day |
| 9 |
Claim 2 strength slice |
10 mg composition |
| 10 |
Claim 2 strength slice |
25 mg composition |
| 11 |
Claim 3 dose slice |
10 mg/day |
| 12 |
Claim 3 dose slice |
25 mg/day |
| 13 |
Claim 4 strength slice |
10 mg composition |
| 14 |
Claim 4 strength slice |
25 mg composition |
| 15 |
Claim 5 dose slice |
10 mg/day |
| 16 |
Claim 5 dose slice |
25 mg/day |
| 17 |
Claim 6 strength slice |
10 mg composition |
| 18 |
Claim 6 strength slice |
25 mg composition |
Key Takeaways
- US 9,949,997 is a dose-specific, patient-subgroup-specific method-of-use patent covering empagliflozin for cardiovascular death, heart failure hospitalization, and all-cause mortality risk reduction in type 2 diabetes patients with cardiovascular disease.
- The method scope is constrained to oral administration of 10 mg or 25 mg total daily empagliflozin, with composition sub-claims for 10 mg or 25 mg strengths.
- Dependent claims split cleanly into 10 mg vs 25 mg administration and 10 mg vs 25 mg composition, strengthening enforcement around real-world dosing and tablet strength.
- For competitors, the highest-risk exposure path is use in the T2DM + cardiovascular disease population at 10 mg/25 mg daily, with labeling/inducement strategies needing to account for outcome-linked claims rather than generic SGLT2 class effects.
FAQs
1) Does US 9,949,997 cover empagliflozin regardless of dose?
No. The claims require oral administration of empagliflozin at 10 mg or 25 mg total daily (and dependent claims further restrict to the specific 10 mg or 25 mg case).
2) Is cardiovascular disease optional or required?
It is required. The patient must have cardiovascular disease for Claims 1, 3, and 5.
3) What endpoints are explicitly claimed?
The patent text provided claims three endpoints:
- cardiovascular death (Claim 1)
- hospitalization for heart failure (Claim 3)
- all-cause mortality (Claim 5)
4) Do composition claims matter if infringement is about prescribing?
Yes. Claims 2, 4, and 6 add composition limitations requiring compositions comprising 10 mg or 25 mg empagliflozin, with further dose-strength dependent claims.
5) Can a competitor lower risk by avoiding 10 mg and 25 mg?
The claims as provided are limited to 10 mg or 25 mg total daily dosing. Avoiding those dose strengths is a direct route to reducing claim fit under the provided language.
References
[1] United States Patent Application / Patent: US 9,949,997 (claims provided in prompt).
